CD Genomics Launched HLA Genotyping Service to Help Scientists Better Understand the Mechanisms of MHC

July 26 17:21 2021

New York, USA – July 26, 2021 – CD Genomics is one of the leading service providers in the area of genomic sequencing and data analysis as well as other genomic-related technologies to fully support customers’ research projects. HLA genotyping service is one such. CD Genomics provides accurate and reliable HLA genotyping service based on next-generation sequencing (NGS) technology that generates unambiguous, phase-resolved HLA sequencing results in a single assay.

Humans’ major histocompatibility complex (MHC) proteins are encoded by the HLA (human leukocyte antigen) system. The human immune system is regulated by these glycoproteins that are part of the cell membrane. MHC is divided into two classes: MHC class I and MHC class II. With over 10,000 different HLA alleles identified to date, they are the most polymorphic gene family in the human genome. Transplant rejection, autoimmune disease, vaccine pharmacogenomics, cancer, and infectious diseases have all been linked to HLA genes. HLA genotyping is the process of determining an individual’s HLA class I and class II gene polymorphisms. The introduction of next-generation sequencing (NGS) has altered the landscape of genotyping, which allows for reliable, simple, high-quality, and high-throughput analysis of the key HLA genes.

A group of scientists from the University of Georgia realized that while the highly immunogenic carrier proteins CRM197 and tetanus toxoid played an important role in immunogenicity and vaccine design alike, their defined human major histocompatibility complex class II (MHCII) T cell epitopes were inadequately characterized. “Our study serves toward understanding carrier protein immune responses. In this research, the HLA typing of each donor was performed by CD Genomics. Alleles of multiple loci were genotyped for each donor,” said the researcher, “hopefully, our findings can help the use of these peptides in developing novel knowledge-based vaccines to combat persisting problems in glycoconjugate vaccine design.”

“HLA genes have many variations. For example, HLA-B27 has hundreds of identified alleles. Their high degree of polymorphism allows an individual’s immune system to respond to a wide range of foreign invaders, and specific versions may be associated with human diseases,” said Chief Scientist of CD Genomics. “Meanwhile, more than 100 diseases have been reported to relate to different alleles of HLA genes. Many diseases, such as ankylosing spondylitis, liver disease, abnormal immune function, and some types of cancer have been linked with specific HLA alleles.” He continued, “That’s how significant HLA typing is, and CD Genomics offers customers superior HLA typing solutions.”

CD Genomics provides HLA typing with flexible testing sites such as HLA class I (A, B, C) and HLA class II (DQB1, DQA1, DPA1, DPB1, DRB1, DRB3, DRB4, DRB5). The capture sequencing protocol enables a cost-effective, fast, and high-throughput manner. With strict quality control and rich practical experience, CD Genomics guarantees high resolution and accuracy, offering extensive data for researchers’ disease studies. (For Research Use Only. Not for use in diagnostic procedures.)

About CD Genomics

CD Genomics is one of the top genomic research service providers, providing reliable services to pharmaceutical and biotech companies as well as academia and government agencies. More than 70% of the scientists in CD Genomics hold a Ph.D. or Master’s degree, all with extensive experience in genomics research. CD Genomics adopts an optimized workflow, efficiently providing both next-generation sequencing and long-read sequencing coupled with a cloud-based platform for bioinformatics analysis.

Media Contact
Company Name: CD Genomics
Contact Person: Kiko Garcia
Email: Send Email
Phone: 1-631-259-7705
Country: United States